Table 6 Multivariable analyses of progression-free survival and overall survival in each treatment arm including baseline biomarkers dichotomized at the median and change in biomarkers at week 4 as covariates
Plasma Biomarker | HR (95% CI) | P value |
|---|---|---|
Progression-Free Survival (Cabozantinib) | ||
HGF | 1.46 (1.02, 2.08) | 0.04* |
VEGF | 1.32 (0.95, 1.83) | 0.10 |
AXL | 1.31 (0.95, 1.79) | 0.10 |
∆HGF | 0.87 (0.70, 1.07) | 0.19 |
GAS6 | 1.08 (0.79, 1.49) | 0.62 |
∆IL-8 | 0.98 (0.90, 1.07) | 0.68 |
Overall Survival (Cabozantinib) | ||
HGF | 2.17 (1.41, 3.35) | < 0.001* |
GAS6 | 1.62 (1.08–2.42) | 0.02* |
VEGF | 1.62 (1.04, 2.53) | 0.03* |
AXL | 1.19 (0.83, 1.72) | 0.34 |
IL-8 | 1.15 (0.76, 1.76) | 0.51 |
∆CA9 | 0.97 (0.87, 1.07) | 0.52 |
∆VEGF | 1.02 (0.93, 1.11) | 0.74 |
∆HGF | 0.98 (0.77, 1.23) | 0.85 |
∆GAS6 | 0.98 (0.6, 1.59) | 0.93 |
∆IL-8 | 1 (0.89, 1.13) | 0.94 |
Progression-Free Survival (Everolimus) | ||
HGF | 1.37 (1.03, 1.82) | 0.03* |
IL-8 | 1.29 (0.97, 1.71) | 0.08 |
Overall Survival (Everolimus) | ||
MET | 1.37 (0.99, 1.90) | 0.06 |
HGF | 1.38 (0.99, 1.93) | 0.06 |
IL-8 | 1.35 (0.95, 1.91) | 0.09 |
GAS6 | 1.20 (0.86, 1.67) | 0.28 |
∆VEGF | 0.96 (0.87, 1.06) | 0.46 |
VEGF | 1.07 (0.74, 1.55) | 0.72 |